DK168767B1 - DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein - Google Patents

DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein Download PDF

Info

Publication number
DK168767B1
DK168767B1 DK481383A DK481383A DK168767B1 DK 168767 B1 DK168767 B1 DK 168767B1 DK 481383 A DK481383 A DK 481383A DK 481383 A DK481383 A DK 481383A DK 168767 B1 DK168767 B1 DK 168767B1
Authority
DK
Denmark
Prior art keywords
protein
expression vector
dna sequence
modified
amino acid
Prior art date
Application number
DK481383A
Other languages
Danish (da)
English (en)
Other versions
DK481383D0 (da
DK481383A (da
Inventor
David F Mark
Leo S Lin
Shi-Da Yu Lu
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27030446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK168767(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of DK481383D0 publication Critical patent/DK481383D0/da
Publication of DK481383A publication Critical patent/DK481383A/da
Application granted granted Critical
Publication of DK168767B1 publication Critical patent/DK168767B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK481383A 1982-10-19 1983-10-19 DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein DK168767B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43515482A 1982-10-19 1982-10-19
US43515482 1982-10-19
US48616283A 1983-04-15 1983-04-15
US48616283 1983-04-15

Publications (3)

Publication Number Publication Date
DK481383D0 DK481383D0 (da) 1983-10-19
DK481383A DK481383A (da) 1984-04-20
DK168767B1 true DK168767B1 (da) 1994-06-06

Family

ID=27030446

Family Applications (2)

Application Number Title Priority Date Filing Date
DK481383A DK168767B1 (da) 1982-10-19 1983-10-19 DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein
DK105892A DK171681B1 (da) 1982-10-19 1992-08-26 DNA-sekvens, der koder for et modificeret human-beta-interferonprotein (IFN-beta), hvori 17-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle, der er transpormeret med ekspressionsvektorer samt fremgangsmåde til fremstilling af det modificerede protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK105892A DK171681B1 (da) 1982-10-19 1992-08-26 DNA-sekvens, der koder for et modificeret human-beta-interferonprotein (IFN-beta), hvori 17-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle, der er transpormeret med ekspressionsvektorer samt fremgangsmåde til fremstilling af det modificerede protein

Country Status (23)

Country Link
EP (4) EP0192811B1 (de)
JP (2) JPS6128392A (de)
KR (1) KR910009900B1 (de)
AT (4) ATE61407T1 (de)
AU (1) AU563962B2 (de)
BE (1) BE898016A (de)
CA (1) CA1340861C (de)
CH (1) CH669395A5 (de)
DE (4) DE3382197D1 (de)
DK (2) DK168767B1 (de)
ES (4) ES8505717A1 (de)
FI (1) FI82266C (de)
FR (1) FR2534594B1 (de)
GB (1) GB2130219B (de)
GR (1) GR79408B (de)
IE (1) IE56026B1 (de)
IL (1) IL69970A (de)
LU (3) LU88761I2 (de)
NL (2) NL930119I2 (de)
NO (1) NO173740C (de)
NZ (1) NZ205922A (de)
PH (2) PH20343A (de)
PT (1) PT77512B (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
NZ208309A (en) * 1983-06-01 1988-04-29 Hoffmann La Roche Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
EP0211835B1 (de) 1984-03-28 1990-01-03 Cetus Corporation Pharmazeutische zusammensetzungen von mikrobenerzeugtem interleukin-2
EP0163603B1 (de) * 1984-05-08 1989-12-13 Genetics Institute, Inc. Ein menschlicher T-Zellwachstumsfaktor
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
CA1275954C (en) 1984-08-31 1990-11-06 Hing Cheug Wong 3'-expression enhancing fragments and method
WO1986002068A1 (en) * 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Mutual separation of proteins
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
DK172052B1 (da) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
DE3500681A1 (de) * 1985-01-11 1986-07-17 Hoechst Ag, 6230 Frankfurt Verfahren zur isolierung und reinigung von lymphokinen
US4863849A (en) * 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
AU595864B2 (en) * 1986-03-14 1990-04-12 Otsuka Pharmaceutical Co., Ltd. Il-1 alpha derivatives and drugs
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
EP0260350B1 (de) * 1986-09-05 1992-02-12 Cetus Oncology Corporation Oxidationsresistente Muteine von beta-Interferon, deren Herstellung und diese Muteine enthaltende Präparate
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
EP0298723A1 (de) * 1987-07-07 1989-01-11 California Biotechnology, Inc. Rekombinante Fibroblasten-Wachstumsfaktoren
ATE163013T1 (de) * 1987-11-04 1998-02-15 Byk Gulden Lomberg Chem Fab Alveolare oberflächenaktive proteine
EP0355460B1 (de) * 1988-08-24 2000-12-27 American Cyanamid Company Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US5079230A (en) * 1988-09-12 1992-01-07 Pitman-Moore, Inc. Stable bioactive somatotropins
CA2003886A1 (en) * 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
JP3207416B2 (ja) * 1989-01-31 2001-09-10 ファルマシア・アンド・アップジョン・カンパニー ソマトトロピン・アナログ類
ES2085329T3 (es) * 1989-02-17 1996-06-01 Merck & Co Inc Agente anticanceroso proteico.
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
US5173297A (en) * 1991-07-01 1992-12-22 Quest International Flavors & Food Ingredients Company Division Of Indopco, Inc. Bacteriocin from lactococcus lactis subspecies lactis
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
FR2671554A1 (fr) * 1991-01-11 1992-07-17 Clonatec Sa Peptides synthetiques derivant de l'antigene hbc du virus de l'hepatite b, leurs applications a la detection d'une infection par ce virus et a la vaccination contre l'hepatite b.
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
DE19544167A1 (de) * 1995-11-17 1997-05-22 Schering Ag Verwendung von Interferon-ß zur Behandlung von Bronchialkarzinom bei Bestrahlungstherapie
WO1997048808A1 (en) * 1996-06-19 1997-12-24 Chiron Corporation Bacterial production of interferon-beta using low levels of sodium and potassium ions
CN1100875C (zh) * 1998-03-06 2003-02-05 上海华晨生物技术研究所 新型重组人白细胞介素2的制备方法及其表达载体和工程菌
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
CA2463935A1 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
KR100511749B1 (ko) * 2001-11-06 2005-09-02 선바이오(주) 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
KR101045401B1 (ko) 2002-09-11 2011-06-30 프레제니우스 카비 도이치란트 게엠베하 하이드록시알킬 전분 유도체
ES2314238T3 (es) 2002-10-08 2009-03-16 Fresenius Kabi Deutschland Gmbh Conjugados de oligosacaridos farmaceuticamente activos.
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
ZA200604419B (en) 2003-11-04 2008-06-25 Novartis Vaccines & Diagnostic Antagonist anti-CD40 monoclonal antibodies and methods for their use
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
DE202005021885U1 (de) 2004-03-11 2011-03-03 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-Protein-Konjugate, durch reduktive Aminierung hergestellt
WO2006015165A2 (en) * 2004-07-26 2006-02-09 Enzon Pharmaceuticals, Inc. Optimized interferon-beta gene
GB0523282D0 (en) 2005-11-15 2005-12-21 Isis Innovation Methods using pores
GB2453377A (en) 2007-10-05 2009-04-08 Isis Innovation Transmembrane protein pores and molecular adapters therefore.
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
EP2085095B1 (de) 2008-01-17 2012-03-07 Philogen S.p.A. Kombination aus einem Anti-EDb-Fibronectin-Antikörper-IL-2-Fusionsprotein und einem B-Zellen bindenden Molekül, B-Zellen-Vorläufern und/oder deren krebserregendem Gegenspieler
CN103695530B (zh) 2008-07-07 2016-05-25 牛津纳米孔技术有限公司 酶-孔构建体
US9447152B2 (en) 2008-07-07 2016-09-20 Oxford Nanopore Technologies Limited Base-detecting pore
US9077937B2 (en) * 2008-11-06 2015-07-07 Alcatel Lucent Method and apparatus for fast channel change
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
KR101797773B1 (ko) 2009-01-30 2017-11-15 옥스포드 나노포어 테크놀로지즈 리미티드 막횡단 시퀀싱에서 핵산 구축물용 어댑터
US20120100530A1 (en) 2009-01-30 2012-04-26 Oxford Nanopore Technologies Limited Enzyme mutant
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
KR101939420B1 (ko) 2011-02-11 2019-01-16 옥스포드 나노포어 테크놀로지즈 리미티드 돌연변이체 세공
CN109432407A (zh) 2011-03-11 2019-03-08 公共事业救济局-巴黎医院 低剂量il-2用于治疗自身免疫相关病症或炎性病症的应用
CN103827320B (zh) 2011-07-25 2017-04-26 牛津纳米孔技术有限公司 使用跨膜孔进行双链多核苷酸测序的发夹环方法
GB201119244D0 (en) 2011-11-08 2011-12-21 British American Tobacco Co Smoking article
CN112646019B (zh) 2012-04-10 2022-08-16 牛津纳米孔科技公开有限公司 突变胞溶素孔
US11155860B2 (en) 2012-07-19 2021-10-26 Oxford Nanopore Technologies Ltd. SSB method
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
KR102168813B1 (ko) 2013-03-08 2020-10-22 옥스포드 나노포어 테크놀로지즈 리미티드 효소 정지 방법
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
US10183061B2 (en) 2013-06-25 2019-01-22 Icm (Institut Du Cerveau Et De La Moelle Epiniere) Boosting Treg cells for treating Alzheimer disease and related disorders
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
EP2918285A1 (de) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 zur Behandlung einer Lebensmittelallergie
CN106574300A (zh) 2014-05-02 2017-04-19 牛津纳米孔技术公司 改善目标多核苷酸相对于跨膜孔移动的方法
CA2959220A1 (en) 2014-09-01 2016-03-10 Vib Vzw Mutant csgg pores
WO2016055778A1 (en) 2014-10-07 2016-04-14 Oxford Nanopore Technologies Limited Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
US10876109B2 (en) 2015-04-24 2020-12-29 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in prokaryotic cells and libraries of prokaryotic cells expressing candidate biologically active random peptides
WO2016172445A2 (en) * 2015-04-24 2016-10-27 The University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
US10801023B2 (en) * 2015-04-24 2020-10-13 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
MX2018004883A (es) 2015-10-22 2018-08-01 Iltoo Pharma Composiciones farmaceuticas de il-2.
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
IL263874B1 (en) 2016-06-22 2024-10-01 David Klatzmann Genetically modified T lymphocytes
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020102556A1 (en) 2018-11-15 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of prognosis and classification for preeclampsia
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
JP2023505590A (ja) 2019-12-12 2023-02-09 イルトゥー・ファルマ インターロイキン２キメラ構築物
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
TW202146041A (zh) 2020-03-06 2021-12-16 尼姆大學醫學中心 用於肌肉萎縮性脊髓側索硬化症之治療的低劑量人類介白素-2
CN116075523A (zh) * 2020-04-29 2023-05-05 基因制药株式会社 具有融合的干扰素-β突变蛋白和抗体的重组蛋白以及包含其的药物组合物
MX2022013662A (es) * 2020-04-29 2023-02-01 Abion Inc Variante del interferon-beta humano con doble mutacion y metodo para mejorar la estabilidad de la variante del interferon-beta humano.
MX2024004291A (es) 2021-10-06 2024-06-28 Iltoo Pharma Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados.
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
WO2024121173A1 (en) 2022-12-05 2024-06-13 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5359688A (en) * 1976-11-11 1978-05-29 Tanpakushitsu Kenkiyuu Shiyour Production of novel polypeptide
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
PT72786B (en) * 1980-04-03 1983-01-10 Biogen Nv Process for producing dna sequences recombinant dna molecules and human fibroplast interferon-like polypeptides
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
NZ208309A (en) * 1983-06-01 1988-04-29 Hoffmann La Roche Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins

Also Published As

Publication number Publication date
DK481383D0 (da) 1983-10-19
PH20343A (en) 1986-12-04
ES8608043A1 (es) 1986-06-01
DE3382197D1 (de) 1991-04-11
DE3380598D1 (en) 1989-10-26
DK105892A (da) 1992-08-26
FI82266B (fi) 1990-10-31
EP0234599A1 (de) 1987-09-02
CH669395A5 (de) 1989-03-15
EP0218825B1 (de) 1989-09-20
IL69970A0 (en) 1984-01-31
ATE61407T1 (de) 1991-03-15
ES542829A0 (es) 1986-06-01
NL930119I2 (nl) 1995-01-16
EP0109748A1 (de) 1984-05-30
PH23702A (en) 1989-09-27
PT77512A (en) 1983-11-01
FR2534594B1 (fr) 1987-06-19
IE832380L (en) 1984-04-19
LU88761I2 (fr) 1996-11-05
GR79408B (de) 1984-10-22
DK481383A (da) 1984-04-20
JPS6128392A (ja) 1986-02-08
ATE73493T1 (de) 1992-03-15
LU90413I2 (fr) 1999-09-07
ES533053A0 (es) 1985-06-16
ATE33503T1 (de) 1988-04-15
EP0234599B1 (de) 1992-03-11
BE898016A (fr) 1984-02-15
DK171681B1 (da) 1997-03-10
EP0109748B1 (de) 1988-04-13
GB2130219A (en) 1984-05-31
NO173740C (no) 1994-01-26
EP0192811A1 (de) 1986-09-03
GB8327490D0 (en) 1983-11-16
FI833681A (fi) 1984-04-20
ATE46539T1 (de) 1989-10-15
IE56026B1 (en) 1991-03-27
FR2534594A1 (fr) 1984-04-20
EP0192811B1 (de) 1991-03-06
KR840006369A (ko) 1984-11-29
NO833793L (no) 1984-04-24
FI833681A0 (fi) 1983-10-10
EP0218825A1 (de) 1987-04-22
JPH0568480B2 (de) 1993-09-29
AU563962B2 (en) 1987-07-30
PT77512B (en) 1987-11-24
DE3376271D1 (en) 1988-05-19
ES533054A0 (es) 1985-08-01
NO173740B (no) 1993-10-18
NL960013I2 (nl) 1997-03-03
AU2008683A (en) 1984-05-03
IL69970A (en) 1991-05-12
ES8506801A1 (es) 1985-08-01
KR910009900B1 (ko) 1991-12-03
NZ205922A (en) 1987-11-27
JPS6420096A (en) 1989-01-24
GB2130219B (en) 1986-01-29
ES526541A0 (es) 1985-04-01
ES8505717A1 (es) 1985-04-01
CA1340861C (en) 1999-12-28
NL960013I1 (nl) 1996-10-01
LU88357I2 (fr) 1994-05-04
NL930119I1 (nl) 1993-11-01
DE3382528D1 (de) 1992-04-16
ES8506089A1 (es) 1985-06-16
DK105892D0 (da) 1992-08-26
FI82266C (fi) 1991-02-11

Similar Documents

Publication Publication Date Title
DK168767B1 (da) DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein
DK172276B1 (da) Rekombinant derivat af human tumornekrosefaktor (hTNF), strukturelt gen, som koder for det rekombinante derivat, ekspressionsvektor, værtsceller, transformeret E. coli, fremgangsmåder til fremstilling af det rekombinante derivat og det strukturelle gen, oligonukleotid til brug ved fremstilling af genet, terapeutiske sammensætninger og formuleringer
Wang et al. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues
US5608036A (en) Enhanced secretion of polypeptides
SE465223B (sv) Moget rekombinant-humanleukocytinterferon och foerfarande foer dess framstaellning
US6268180B1 (en) Recombinant human recombinant human interleukin-1α
EP0212914A2 (de) Erhöhung der Expression von rekombinanten DNS-Produkten
JP2533470B2 (ja) 豚成長ホルモンを生産するためのｄｎａ配列，組換ｄｎａ分子および生産方法
US4762914A (en) Truncated protein of interleukin-1
EP0592566B1 (de) Cysteinfreie il-6 mutanten
US5077219A (en) Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
EP0370052A1 (de) Menschliche granulocyte-macrophage-kolonie, stimulierender faktor und muteine daraus
EP0194006B1 (de) Analoge Interferon-Polypeptide, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US5106735A (en) Cloning of a dna sequence encoding a sarcophaga peregrina antibacterial polypeptide precursor
KR0133252B1 (ko) 내열성의 알파-1-안티트립신 뮤테인
US5017486A (en) Cloning of DNA encoding antibacterial polypeptide precursor
JPH02195888A (ja) ヒトインターロイキン２活性を有するポリペプチドをコードする遺伝子を含有する組換えｄｎａ体および該組換えｄｎａ体により形質転換された原核生物細胞
EP0267795A2 (de) Muteine des Maus-Interleukin-2
EP0190163A1 (de) Wachstumshormon
AU2131688A (en) Human granulocyte-macrophage colony stimulating factor and muteins thereof
NO306951B1 (no) DNA-sekvens som koder for et modifisert human-IFM-(beta) samt fremgangsmåte for fremstilling derav
KR20020003917A (ko) 꼬리 단백질과 인간 인터루킨-16의 융합 단백질, 이 융합단백질을 코딩하는 유전자, 이 유전자를 포함하는 발현벡터, 이 벡터로 형질전환된 대장균 및 이 대장균을이용한 인간 인터루킨-16의 생산 방법
NO863976L (no) Cystein-beroevede muteiner av biologisk aktive human tumornekrosefaktorproteiner.
JPH0646866A (ja) 耐熱性カルボキシペプチダーゼをコードする遺伝子及びそれを用いた耐熱性カルボキシペプチダーゼの生産方法

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1994 00012, 941205

CTFG Supplementary protection certificate (spc) issued

Free format text: CA 1994 00012, 941205, EXPIRES: 20040703

PUP Patent expired